PATENT CLAIM ANALYSIS

Application Number: 15875695
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "131100"]

Abstract:
Methods and compositions for enhancing an immune response in a subject (e.g., an immunocompromised subject or a subject with systemic lupus erythematosus (SLE)) are described. In particular, methods of administering to the subject an effective amount of an anti-signaling lymphocytic activation molecule family member 7 (SLAMF7)-antibody or antigen binding fragment thereof are described.

Claim (Index 11):
A method of enhancing degranulation and cytotoxicity of CD8+ T cells in a subject in need of treatment of systemic lupus erythematosus (SLE), the method comprising administering to the subject an effective amount of an antibody that binds a signaling lymphocytic activation molecule family member 7 (SLAMF7), or an antigen binding fragment thereof, wherein administration of the antibody that binds SLAMF7, or an antigen binding fragment thereof to the subject results in an enhancement of degranulation and cytotoxicity of CD8+ T cells in the subject in need of treatment of SLE.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 86.0
- Lexical Diversity: 1.3617
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14935937', '15142538', '15661584', '10466023', '15239569']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6972817676346015
- 35 USC 102 Novelty (BERT): 0.5237524733266504
- Combined Prediction Score: 0.6799288382038065
- Mean Citation Score: 306.377952
- Max Citation Score: 315.16696
- Similarity Product: 226.35346425562847

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test